Anti-angiogenic activity of carebastine: a plausible mechanism affecting airway remodelling Source: Eur Respir J 2009; 34: 958-966 Year: 2009
Tiotropium and olodaterol exert anti-proliferative effects on pulmonary fibroblasts of asthmatic patients in vitro Source: Annual Congress 2013 –Airway smooth muscle and cell biology Year: 2013
CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018
Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014
TSPO a new anti-inflammatory target in the airway of COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013
Pharmacological characterisation of indacaterol (QAB149), a novel once-daily inhaled β2 -agonist, on small airways in human and rat lung slices Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006
Antiproliferative effects of drugs affecting different signalling pathways on rat and human pulmonary artery smooth muscle cells Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015
Gene therapeutic approaches: from stem cell therapy to gene delivery Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine Year: 2006
Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma Source: Eur Respir J 2006; 27: 172-187 Year: 2006
Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics Source: International Congress 2015 – New models for treating airway diseases Year: 2015
Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021
Sildenafil is a potent pulmonary vasodilator in pulmonary hypertension associated with interstitial lung disease: impact on gas exchange properties Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002
Anti-fibrotic effects of pirfenidone on pulmonary arterial vascular smooth muscle cells Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016
HDAC2-independent anti-inflammatory effects of budesonide in human lung fibroblasts Source: Annual Congress 2011 - Recent developments in COPD Year: 2011
Effect of drugs with pleiotropic properties on tone of pulmonary arteries and bronchi in obstructive lung pathology model Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015
Pulmonary surfactant as drug delivery system to target lung epithelium: new approach for the treatment of epithelial injury after bleomycin challenge Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018
Inhaled glucocorticosteroid treatment effects on pulmonary artery pressure and cardiac function in healthy smokers Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016
Enhanced anti-inflammatory gene expression in humans following inhaled budesonide Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013